GlassScriptPhysician profile
Jeanette Cancel
NPI 1740246644
$10,621.72
in general payments reported to CMS, 2019-2025
21 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,453 · 2020: $459 · 2021: $878 · 2022: $1,295 · 2023: $1,096 · 2024: $1,669 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,536.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,687.13 | 2019-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $3,195.60 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Theratechnologies INC. | $750.91 | 2019-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $739.74 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $463.88 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $159.73 | 2019-2025 | Mytesi |
| Janssen Products, LP | $99.95 | 2019 | |
| Abbvie INC. | $83.98 | 2023-2025 | Mavyret |
| Exact Sciences Corporation | $62.09 | 2024-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $52.84 | 2023-2024 | Aptima, Affirm Prone Biopsy System |
| Sk Life Science, INC. | $49.82 | 2020 | |
| Janssen Scientific Affairs, LLC | $41.56 | 2021-2023 | Symtuza |
| Novo Nordisk INC | $41.36 | 2025 | |
| Aimmune Therapeutics, INC. | $31.84 | 2025 | Vowst |
| Emd Serono, INC. | $31.70 | 2019-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Lilly USA, LLC | $24.91 | 2024 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $23.91 | 2023 | Ingrezza |
| Glaxosmithkline, LLC. | $19.46 | 2025 | Shingrix |
| Vbi Vaccine (Delaware) INC. | $17.03 | 2023 | Prehevbrio |
| Amgen INC. | $15.80 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanette Cancel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.